Innovative drug development for headache disorders / edited by Jes Olesen, Nabih Ramadan.

Format:

Book

Contributor:

Olesen, Jes.

Ramadan, Nabih.

Series:

Frontiers in headache research ; v. 16.

Frontiers in headache research series ; v. 16

Language:

English

Subjects (All):

Analgesics.

Drug development.

Headache--Chemotherapy.

Headache.

Physical Description:

1 online resource (240 p.)

Place of Publication:

Oxford ; New York : Oxford University Press, 2008.

Language Note:

English

Summary:

Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do nottolerate them. It is now clear that, even with effective treatment, patients with frequent migraine attacks are no

Contents:

Contents; Preface; Contributors; Session I: Screening models; 1 The human γ-aminobutyric acid transporter GAT-2: from cloning to high throughput screening; 2 Low through put preclinical models for headache; 3 Human models: screening models; Session II: Trials methodology; 4 Stricter success criteria, qualitative and quantitative end-points: acute versus prevention trials; 5 Health-related quality of life and similar end-points; 6 Clinically relevant designs and outcome measures for acute migraine trials

7 Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification8 Discussion summary: Trials methodology; Session III: Nitric oxide and spreading depression modulators; 9 Inducible nitric oxide synthase and development of new migraine treatments; 10 Mechanisms of cortical spreading depression as targets for migraine therapy; 11 Tonabersat; 12 Discussion summary: Nitric oxide and spreading depression modulators

Session IV: Calcitonin gene-related peptide and 5-hydroxytryptamine modulators13 Calcitonin gene-related peptide: relevance for migraine; 14 New 5-hydroxytryptamine-related drug targets; 15 Effect of two novel calcitonin gene-related peptide-binding compounds in a closed cranial window rat model; 16 Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment; 17 Discussion summary: Calcitonin gene-related peptide and 5-hydroxytryptamine modulators; Session V: Ion channel modulators and antiepileptics

18 Migraine: from genes to pathophysiology - transgenic mouse models of migraine19 K[sub(ATP)] channels and migraine; 20 Antiepileptic drugs and migraine; 21 Discussion summary: Ion channel modulators and antiepileptics; Session VI: Other future targets for headache therapy; 22 Innovative drug development for headache disorders: glutamate; 23 The modulation of TRPV1 channels by cannabinoid[sub(1)] receptors; 24 Future targets for headache therapy: prostanoids; 25 Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat; Index; A; B; C; D; E; F; G; H; I; K

LM; N; O; P; Q; R; S; T; V; W; Y; Z

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

ISBN:

0-19-176883-9

1-283-58044-6

9786613892898

0-19-156462-1

OCLC:

801363524